Disc Medicine secures $200M in debt financing from Hercules Capital

seekingalpha

2024-11-09

Disc Medicine (NASDAQ:IRON) has obtained a $200M non-dilute term loan facility from Hercules Capital (NYSE:HTGC).
Funding can support development across the portfolio, including the potential accelerated approval pathway for bitopertin in EPP.
The loan facility consists of up to four tranches, three of which can be drawn at Disc’s option and each maturing in November 2029.
An initial $30M tranche was funded at closing, with an additional $80M available to be drawn at Disc’s option. An additional $65M is available subject to Disc's achievement of specified performance milestones. The final $25M tranche is available for draw, at Disc’s option and subject to Hercules consent, during the interest-only period.
Shares of Disc Medicine rose 3% on Friday.
Source: Press Release

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2482676481"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2482676481\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2482676481?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-09 00:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2482676481","market":"us","top_or_hot":-1,"title":"Disc Medicine secures $200M in debt financing from Hercules Capital","media":"seekingalpha","content":"<html><body><ul> <li><a href=\"https://laohu8.com/S/IRON\">Disc Medicine</a> (<span>NASDAQ:IRON</span>) has obtained a $200M non-dilute term loan facility from Hercules Capital (<span>NYSE:HTGC</span>). </li> <li>Funding can support development across the portfolio, including the potential accelerated approval pathway for bitopertin in EPP.</li> <li>The loan facility consists of up to four<span> tranches, three of which can be drawn at Disc’s option and each maturing in November 2029.</span> </li> <li>An initial $30M tranche was funded at closing, with an additional $80M available to be drawn at Disc’s option. An additional $65M is available subject to Disc's achievement of specified performance milestones. The final $25M tranche is available for draw, at Disc’s option and subject to Hercules consent, during the interest-only period.</li> <li>Shares of Disc Medicine rose 3% on Friday. </li> <li>Source: Press Release </li> </ul> </body></html>","source":"seekingalpha_trending_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Disc Medicine secures $200M in debt financing from Hercules Capital</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDisc Medicine secures $200M in debt financing from Hercules Capital\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-09 00:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4266732-disc-medicine-secures-200-m-in-debt-financing-from-hercules-capital><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Disc Medicine (NASDAQ:IRON) has obtained a $200M non-dilute term loan facility from Hercules Capital (NYSE:HTGC).  Funding can support development across the portfolio, including the potential ...</p>\n\n<a href=\"https://seekingalpha.com/news/4266732-disc-medicine-secures-200-m-in-debt-financing-from-hercules-capital\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4135","symbol_name":"资产管理与托管银行","start_time":0,"source_url":"https://seekingalpha.com/news/4266732-disc-medicine-secures-200-m-in-debt-financing-from-hercules-capital","article_id":"2482676481","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482676481","pubTimestamp":1731083156,"columns":[],"sourceInfo":{"source_id":"seekingalpha_trending_news","name":"Seeking Alpha Trending News"},"weMediaInfo":null,"summary":"Disc Medicine  has obtained a $200M non-dilute term loan facility from Hercules Capital .  Funding can support development across the portfolio, including the potential accelerated approval pathway for bitopertin in EPP. The loan facility consists of up to four tranches, three of which can be drawn at Disc’s option and each maturing in November 2029.  An initial $30M tranche was funded at closing, with an additional $80M available to be drawn at Disc’s option. An additional $65M is available subject to Disc's achievement of specified performance milestones. The final $25M tranche is available for draw, at Disc’s option and subject to Hercules consent, during the interest-only period. Shares of Disc Medicine rose 3% on Friday.  Source: Press Release","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4135":"资产管理与托管银行","IRON":"Disc Medicine","HTGC":"海格投资","BK4139":"生物科技"},"translate_title":"Disc Medicine从Hercules Capital获得2亿美元债务融资","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HTGC":1,"IRON":1},"content_text":"Disc Medicine (NASDAQ:IRON) has obtained a $200M non-dilute term loan facility from Hercules Capital (NYSE:HTGC).  Funding can support development across the portfolio, including the potential accelerated approval pathway for bitopertin in EPP. The loan facility consists of up to four tranches, three of which can be drawn at Disc’s option and each maturing in November 2029.  An initial $30M tranche was funded at closing, with an additional $80M available to be drawn at Disc’s option. An additional $65M is available subject to Disc's achievement of specified performance milestones. The final $25M tranche is available for draw, at Disc’s option and subject to Hercules consent, during the interest-only period. Shares of Disc Medicine rose 3% on Friday.  Source: Press Release","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}